A new study suggests that a combination of radiation therapy and immune checkpoint inhibitors (ICIs) may offer a less ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

Moderna (MRNA) has been a classic example of how one successful product can propel a biotech stock to new heights in a matter ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...

What are the signs and symptoms of bladder cancer, and what are its risk factors? Here's what you need to know, according to an expert.

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

Piper Sandler analyst Allison Bratzel initiated coverage of enGene (ENGN) with an Overweight rating and $26 price target The non-muscle ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 Genitourinary Cancers Symposium ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.